ML311 is a potent and selective inhibitor of soluble epoxide hydrolase (sEH), an enzyme that metabolizes anti-inflammatory epoxy fatty acids. It is primarily utilized in medicinal chemistry and drug discovery to elevate levels of these bioactive lipids, showing promise in modulating inflammation, pain, and related pathways. Research highlights its potential in treating inflammatory conditions, cardiovascular diseases, and certain cancers by inhibiting tumor-promoting inflammation. Additionally, studies explore its neuroprotective effects in neurological disorders and metabolic issues. ML311 is commonly employed in preclinical models to elucidate disease mechanisms, assess therapeutic efficacy, and evaluate safety profiles.